This is of relevance for the design of next-line therapies for melanomas with acquired PLX4032 resistance since ABC transporters including ABCB1, ABCC1, and ABCG2 confer multi-drug resistance [10–12]. The gene discussed is ABCG2; the disease is melanoma.